235 related articles for article (PubMed ID: 22171635)
1. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
Ayala-Breton C; Barber GN; Russell SJ; Peng KW
Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
[TBL] [Abstract][Full Text] [Related]
2. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
3. Virus entry is a major determinant of cell tropism of Edmonston and wild-type strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins.
Tatsuo H; Okuma K; Tanaka K; Ono N; Minagawa H; Takade A; Matsuura Y; Yanagi Y
J Virol; 2000 May; 74(9):4139-45. PubMed ID: 10756026
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
5. Targeted cell entry of lentiviral vectors.
Funke S; Maisner A; Mühlebach MD; Koehl U; Grez M; Cattaneo R; Cichutek K; Buchholz CJ
Mol Ther; 2008 Aug; 16(8):1427-36. PubMed ID: 18578012
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E
Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404
[TBL] [Abstract][Full Text] [Related]
7. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
9. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
10. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.
Kneissl S; Abel T; Rasbach A; Brynza J; Schneider-Schaulies J; Buchholz CJ
PLoS One; 2012; 7(10):e46667. PubMed ID: 23071609
[TBL] [Abstract][Full Text] [Related]
11. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.
Schnell MJ; Buonocore L; Kretzschmar E; Johnson E; Rose JK
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11359-65. PubMed ID: 8876140
[TBL] [Abstract][Full Text] [Related]
12. Chimeric measles viruses with a foreign envelope.
Spielhofer P; Bächi T; Fehr T; Christiansen G; Cattaneo R; Kaelin K; Billeter MA; Naim HY
J Virol; 1998 Mar; 72(3):2150-9. PubMed ID: 9499071
[TBL] [Abstract][Full Text] [Related]
13. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.
Uhlig KM; Schülke S; Scheuplein VA; Malczyk AH; Reusch J; Kugelmann S; Muth A; Koch V; Hutzler S; Bodmer BS; Schambach A; Buchholz CJ; Waibler Z; Scheurer S; Mühlebach MD
J Virol; 2015 Sep; 89(17):9044-60. PubMed ID: 26085166
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
Peng KW; Donovan KA; Schneider U; Cattaneo R; Lust JA; Russell SJ
Blood; 2003 Apr; 101(7):2557-62. PubMed ID: 12433686
[TBL] [Abstract][Full Text] [Related]
16. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat-containing G protein-coupled receptor 4 facilitates vesicular stomatitis virus infection by binding vesicular stomatitis virus glycoprotein.
Zhang N; Huang H; Tan B; Wei Y; Xiong Q; Yan Y; Hou L; Wu N; Siwko S; Cimarelli A; Xu J; Han H; Qian M; Liu M; Du B
J Biol Chem; 2017 Oct; 292(40):16527-16538. PubMed ID: 28842478
[TBL] [Abstract][Full Text] [Related]
18. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
19. DARPins: an efficient targeting domain for lentiviral vectors.
Münch RC; Mühlebach MD; Schaser T; Kneissl S; Jost C; Plückthun A; Cichutek K; Buchholz CJ
Mol Ther; 2011 Apr; 19(4):686-93. PubMed ID: 21224833
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.
Ayala Breton C; Wikan N; Abbuhl A; Smith DR; Russell SJ; Peng KW
Mol Ther Oncolytics; 2015; 2():15012. PubMed ID: 27119107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
